Challenging Node-positive Case Studies Webinar

September 23, 2021, 5:30PM PT

Hear Drs. Jeremy Force and Christy Russell discuss how physicians can use the Breast Recurrence Score test and the recently presented data from the RxPONDER trial to inform chemotherapy decisions.

Product Theater at CAP 2021

September 27, 2021, 9:45AM-10:45AM PT

Join us at CAP to learn more about a Pathologist’s perspective on CGP and how the Oncotype MAP Pan-Cancer Tissue test has been used to guide therapy selection in NSCLC in the webinar "What Can We Learn from NSCLC? A Pathologist’s Perspective on Using Comprehensive Genomic Profiling to Enhance Patient Care".

UroCareLive Webinar

Available Now On-Demand

Drs. Sellinger and Shore discuss “Incorporating Genomic Profiling and Biomarker Testing in Clinical Practice” using the Oncotype tests for advanced prostate cancer patients.

New Cut Point for Unfavorable Intermediate and High-Risk Patients

Oncotype DX Genomic Prostate Score

The Oncotype DX GPS assay stratifies unfavorable intermediate and high-risk patients into two distinct groups with highly differing long-term outcomes.

Medicare Coverage Update

Oncotype DX Genomic Prostate Score

The Oncotype DX Genomic Prostate Score Assay is now covered by Medicare for all intermediate-risk prostate cancer patients.
Making cancer care smarter.™